Sunshine Biopharma (SBFM) Operating Expenses (2010 - 2026)

Sunshine Biopharma has reported Operating Expenses for 16 years, with the latest figure at $4.5 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 14.38% year-over-year to $4.5 million; the trailing twelve-month figure through Mar 2026 stood at $22.4 million (up 6.93% YoY), and the FY2025 full-year result was $23.1 million, up 11.88% from the prior year.
• Operating Expenses for Q1 2026 stood at $4.5 million, down from $6.4 million in the prior quarter.
• The five-year high for Operating Expenses was $24.9 million in Q4 2022, with the low at $819650.0 in Q2 2022.
• Historically, Operating Expenses has averaged $5.5 million across 5 years, with a median of $4.8 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Expenses surged 6161.52% — and 2023, when it plunged 78.74%.
• Sunshine Biopharma's Operating Expenses stood at $24.9 million in 2022, then sank by 78.74% to $5.3 million in 2023, then grew by 16.59% to $6.2 million in 2024, then rose by 2.89% to $6.4 million in 2025, then decreased by 29.48% to $4.5 million in 2026.
• The last three Operating Expenses figures came in at $4.5 million (Q1 2026), $6.4 million (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.